Sign In
Buy RPRX
$53.57
+0.610 (+1.15%)
At Close: Jun 22, 2026
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™
04:01pm, Monday, 04'th Nov 2024
Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenib Expected to fund Company through profitability; proforma cash approaching $800 m
Unveiling Royalty Pharma (RPRX) Q3 Outlook: Wall Street Estimates for Key Metrics
10:20am, Friday, 01'st Nov 2024
Beyond analysts' top -and-bottom-line estimates for Royalty Pharma (RPRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the
Why Investors Need to Take Advantage of These 2 Finance Stocks Now
09:55am, Monday, 21'st Oct 2024
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
3 Dividend Growth Stocks to Buy Now for a Lifetime of Passive Income
06:24am, Sunday, 20'th Oct 2024
Buy these stocks now, and the yield on your original investment could reach a double-digit percentage long before you retire.
Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024
04:15pm, Wednesday, 16'th Oct 2024
NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2024 financial results on Wednesday, November 6, 2024 before the U.S
Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Monday, 14'th Oct 2024
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Investors Need to Take Advantage of These 2 Finance Stocks Now
09:50am, Monday, 14'th Oct 2024
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Royalty Pharma Declares Fourth Quarter 2024 Dividend
08:15am, Friday, 11'th Oct 2024
NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2024 of $0.21 per Class A ordin
What Makes Royalty Pharma (RPRX) a New Buy Stock
01:01pm, Tuesday, 08'th Oct 2024
Royalty Pharma (RPRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2 No-Brainer Dividend Stocks to Buy With $100 in October
04:43am, Tuesday, 01'st Oct 2024
With their high yields and strong underlying businesses, these stocks are hard to pass up.
2 High-Yield Dividend Stocks Near 52-Week Lows: Are They Buys Now?
04:56am, Saturday, 28'th Sep 2024
At less than 8 times trailing earnings, Western Union looks like a bargain. Royalty Pharma could grow its specialty financing business much faster than its recent valuation suggests.
3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade
05:23am, Monday, 16'th Sep 2024
Brookfield Renewable Partners offers a juicy dividend yield that could rise steadily along with electricity demand. Royalty Pharma's portfolio of pharmaceutical products is growing by leaps and bounds
2 Unstoppable Dividend Growth Stocks You Can Buy Now With $100
04:56am, Sunday, 08'th Sep 2024
A bear market could be around the corner, but it probably won't stop Bristol Myers Squibb and Royalty Pharma from rapidly raising their dividend payouts. Bristol Myers Squibb has increased its dividen
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
05:14pm, Tuesday, 03'rd Sep 2024
Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes Proceeds to support c
Royalty Pharma to Present at Morgan Stanley's 22nd Annual Global Healthcare Conference
04:15pm, Wednesday, 28'th Aug 2024
NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Morgan Stanley's 22nd Annual Health Care Conference on Sept
